Here are the latest quarterly results of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA financial fact sheet and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 9,270 | 9,489 | 12,409 | 12,091 | 12,068 | 13,413 | 14,571 | 13,143 | |
Other income | Rs m | 34 | 33 | 4 | 4 | 9 | 3 | 32 | 25 | |
Turnover | Rs m | 9,303 | 9,522 | 12,412 | 12,095 | 12,077 | 13,416 | 14,603 | 13,169 | |
Expenses | Rs m | 7,489 | 7,240 | 8,954 | 8,841 | 8,793 | 9,340 | 10,137 | 9,492 | |
Gross profit | Rs m | 1,783 | 1,964 | 3,455 | 3,251 | 3,167 | 4,074 | 4,434 | 3,651 | |
Depreciation | Rs m | 300 | 354 | 360 | 418 | 441 | 415 | 438 | 470 | |
Interest | Rs m | 51 | 50 | 71 | 74 | 77 | 67 | 45 | 23 | |
Profit before tax | Rs m | 1,467 | 1,593 | 3,029 | 2,763 | 2,657 | 3,595 | 3,984 | 3,183 | |
Tax | Rs m | 149 | 360 | 525 | 486 | 621 | 668 | 730 | 591 | |
Profit after tax | Rs m | 1,318 | 1,233 | 2,504 | 2,277 | 2,035 | 2,927 | 3,254 | 2,592 | |
Gross profit margin | % | 19.2 | 20.7 | 27.8 | 26.9 | 26.2 | 30.4 | 30.4 | 27.8 | |
Effective tax rate | % | 10.2 | 22.6 | 17.3 | 17.6 | 23.4 | 18.6 | 18.3 | 18.6 | |
Net profit margin | % | 14.2 | 13.0 | 20.2 | 18.8 | 16.9 | 21.8 | 22.3 | 19.7 | |
Diluted EPS | Rs | 7.0 | 6.5 | 13.3 | 12.1 | 10.8 | 15.5 | 17.3 | 13.7 | |
Diluted EPS (TTM) | Rs | 31.4 | 33.2 | 35.9 | 38.9 | 42.7 | 51.7 | 55.7 | 57.3 | |
![]() |
Read: ALEMBIC PHARMA 3QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: TORRENT PHARMA SHASUN PHARMA LUPIN WOCKHARDT PROCTER & GAMBLE HEALTH
Compare ALEMBIC PHARMA With: TORRENT PHARMA SHASUN PHARMA LUPIN WOCKHARDT PROCTER & GAMBLE HEALTH
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More